MedTrace Logo

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

NCT02467400 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2019-02-06

No results posted yet for this study

Summary

This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.

Conditions

  • Osteoporosis, Age-Related

Interventions

DRUG

Atenolol

beta blocker

DRUG

Nebivolol

beta blocker

DRUG

Propranolol

beta blocker

DRUG

placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • Sundeep Khosla, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2017-10-26
Completion
2018-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02467400 on ClinicalTrials.gov